VA study of 4108 RA-ILD (2006-21). PRED use was 65-77%, A& 1st line Rx (MMF, AZA, RTX, CTX) incr after ILD, use was low (1.2-12%). MTX decr (47 to 30%), but LEF, TNFi, ABA incr. Predictors of ILD Rx: FVC, CCP+, ILD Dx after 2012. https://t.co/GT3Vwo11w1 https://t.co/KFDKsjkN0k
Links:
Real‐World Treatment Patterns in Rheumatoid Arthritis–Associated Interstitial L…
https://acrjournals.onlinelibrary.wiley.com/doi/full/10.1002/acr2.90135
Aug-24-2026


